CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.

Conley, Sarah J; Baker, Trenton L; Burnett, Joseph P; Theisen, Rebecca L; Lazarus, Douglas; Peters, Christian G; Clouthier, Shawn G; Eliasof, Scott; Wicha, Max S

Conley, Sarah J; Baker, Trenton L; Burnett, Joseph P; Theisen, Rebecca L; Lazarus, Douglas; Peters, Christian G; Clouthier, Shawn G; Eliasof, Scott; Wicha, Max S.

Affiliation

Conley SJ; Comprehensive Cancer Center, Department of Internal medicine, University of Michigan, Ann Arbor, MI, USA.

Breast Cancer Res Treat ; 150(3): 559-67, 2015 Apr.

Article in En | MEDLINE | ID: mdl-25833208

Subject(s)

Camptothecin/administration & dosage; Cyclodextrins/administration & dosage; Drug Resistance, Neoplasm/drug effects; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism; Mammary Neoplasms, Experimental/drug therapy; Neoplastic Stem Cells/drug effects; Angiogenesis Inhibitors/administration & dosage; Angiogenesis Inhibitors/pharmacology; Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab/administration & dosage; Bevacizumab/pharmacology; Camptothecin/pharmacology; Cell Line, Tumor; Cyclodextrins/pharmacology; Female; Humans; MCF-7 Cells; Mammary Neoplasms, Experimental/metabolism; Mammary Neoplasms, Experimental/pathology; Mice; Xenograft Model Antitumor Assays

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplastic Stem Cells / Camptothecin / Drug Resistance, Neoplasm / Cyclodextrins / Hypoxia-Inducible Factor 1, alpha Subunit / Mammary Neoplasms, Experimental Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Breast Cancer Res Treat Year: 2015 Document type: Article Affiliation country: United States Country of publication: Netherlands

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google